Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesTscan Therapeutics Inc

Tscan Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.1913 USD 0.00 ( 1.76%)
Last update at 2026-11-09T17:46:00Z
VOLUME
287676
Market Cap
462.02M

Momentum Score

…

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.18
Low
0.20
High
52 Week Price Range
1.93
Low
9.69
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Tscan Therapeutics develops T-cell receptor (TCR) engineered cell therapies and a TCR-discovery platform to identify tumor-specific receptors for oncology applications. Long-term growth drivers include clinical-stage progress of its pipeline, validation and licensing of its discovery technology, and broader adoption of TCR-based adoptive cell therapies which may benefit from advances in immuno-oncology and manufacturing.
Material risks include high clinical and execution risk as an early-stage company with no approved products, ongoing cash burn and likely future financing needs, manufacturing complexity, and intense competition from CAR-T and other immunotherapy approaches.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.19
Dividend Yield
-
Revenue TTM
21.05M
Revenue Per Share
0.32
Gross Profit TTM
-46.28M
Debt / Equity
0.61
ROE
-71.29%
Net Debt
-40.93M
ROCE
-27.50%
Diluted EPS TTM
-0.78

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -66.22M -48.62M -26.13M -13.66M
Net income -65.81M -48.62M -26.02M -13.11M
Selling general administrative 20.35M 13.83M 6.74M 4.77M
Gross profit 13.54M 10.14M 1.08M -
Reconciled depreciation 5.14M 3.33M 1.23M 0.52M
Ebit -66.64M -48.64M -26.23M -14.21M
Ebitda -65.05M -45.31M -25.00M -13.69M
Depreciation and amortization 1.59M 3.33M 1.23M 0.52M
Non operating income net other 0.41M - - -
Operating income -66.64M -48.64M -26.23M -14.21M
Other operating expenses 80.17M 58.78M 27.32M 14.21M
Interest expense 1.18M 0.02M 0.00M 0.00M
Interest income 1.59M - 0.11M 0.55M
Net interest income 0.41M 0.02M 0.11M 0.55M
Income tax expense -0.41M -0.02M -0.11M -0.55M
Total revenue 13.54M 10.14M 1.08M 0.00M
Total operating expenses 80.17M 58.78M 27.32M 14.21M
Total other income expense net 0.41M 0.02M 0.11M 0.55M
Net income from continuing ops -66.22M -48.64M -26.13M -13.66M
Net income applicable to common shares -66.22M -48.62M -26.13M -13.66M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 272.15M 199.09M 188.11M 49.74M 49.38M
Other current assets 2.19M 4.10M 4.25M 1.65M 0.61M
Total liab 121.28M 99.66M 27.33M 92.20M 66.52M
Total stockholder equity 150.87M 99.43M 160.78M -42.46M -17.14M
Other current liab 10.72M 6.84M 6.52M 2.49M 0.03M
Common stock 0.01M 0.00M 0.00M 0.00M -
Capital stock 0.01M 0.00M 0.00M 0.00M 0.00M
Retained earnings -247.60M -158.38M -92.16M -43.53M -17.41M
Other liab - 0.05M 1.59M 9.05M -
Other assets - 5.76M 5.20M 0.76M 0.59M
Cash 133.36M 120.03M 161.41M 34.79M 41.76M
Total current liabilities 29.82M 17.30M 21.34M 17.45M 2.40M
Current deferred revenue 10.14M 3.87M 11.41M 10.63M 0.91M
Net debt -40.93M -34.04M -155.36M -27.36M -36.88M
Short term debt 6.59M 3.68M 1.65M 1.42M 0.44M
Short long term debt 3.35M - - - -
Short long term debt total 92.43M 85.98M 6.04M 7.43M 4.89M
Other stockholder equity 398.46M 257.81M 252.93M 1.07M 0.27M
Property plant equipment - 10.10M 11.77M 12.53M 6.41M
Total current assets 194.24M 120.03M 165.65M 36.45M 42.38M
Net tangible assets - 99.43M 160.78M -42.46M -17.14M
Short term investments 58.69M - - - -
Long term debt 26.70M 29.29M - - -
Accounts payable 2.37M 2.91M 1.76M 2.91M 1.01M
Accumulated other comprehensive income - - -188.11M - -
Common stock total equity - 0.00M 0.00M 0.00M 0.03M
Retained earnings total equity - -158.38M -92.16M - -
Non currrent assets other 1.65M 9.86M 5.20M 0.76M 0.59M
Non current assets total 77.91M 79.06M 22.45M 13.29M 7.00M
Capital lease obligations 62.39M 56.69M 6.04M 7.43M 4.89M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -4.22M -9.94M -4.24M -1.25M
Change to liabilities 1.26M 3.24M 20.57M 0.16M
Total cashflows from investing activities -4.22M -9.94M -4.24M -1.25M
Net borrowings 29.03M 29.35M 29.35M 29.35M
Total cash from financing activities 29.36M 189.67M 0.29M 34.81M
Change to operating activities -1.73M 0.63M 0.79M 0.14M
Net income -66.22M -48.62M -26.13M -13.66M
Change in cash -41.37M 131.05M -6.97M 21.04M
Begin period cash flow 166.44M 35.39M 42.36M 21.32M
End period cash flow 125.06M 166.44M 35.39M 42.36M
Total cash from operating activities -66.50M -48.68M -3.02M -12.52M
Issuance of capital stock 0.19M 189.38M 0.00M 34.81M
Depreciation 5.14M 3.33M 1.23M 0.52M
Sale purchase of stock 0.33M 189.67M - -
Other cashflows from financing activities 29.49M 100.02M -4.24M -1.25M
Change to netincome 4.55M 2.52M 0.52M 0.32M
Capital expenditures 4.22M 9.94M 4.24M 1.25M
Cash flows other operating -11.23M -9.14M - -
Cash and cash equivalents changes -41.37M 131.05M - -
Change in working capital -10.23M -5.90M 21.36M 0.30M
Stock based compensation 4.55M 2.52M 0.52M 0.24M
Other non cash items 0.26M -125.36M 0.00M 0.08M
Free cash flow -70.73M -58.62M -7.26M -13.77M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TCRX
Tscan Therapeutics Inc		 0.00
1.76%		 0.19 - - 17.64 2.48 13.02 -3.42
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Tscan Therapeutics Inc

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

830 Winter Street, Waltham, MA, United States, 02451

857 399 9500

https://www.tscan.com

154

Name Title Year Born
Mr. David P. Southwell Pres, CEO & Director 1961
Mr. Brian Michael Silver J.D. Sr. VP, CFO & Treasurer 1969
Dr. Gavin MacBeath Ph.D. Chief Scientific & Operations Officer 1970
Dr. Stephen J. Elledge Ph.D. Co-Founder & Chairman of Scientific Advisory Board NA
Mr. Tomasz Kula Ph.D. Co-Founder & Member of Advisory Board NA
Mr. Ray Lockard VP of Technical Operations & Quality NA
Ms. Heather Savelle VP of Investor Relations NA
Dr. Zoran Zdraveski J.D., Ph.D. Chief Legal Officer & Company Sec. 1970
Ms. Ann Hargraves VP of HR NA
Dr. William Desmarais M.B.A., Ph.D. Chief Bus. Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…